195
edits
Changes
no edit summary
[[Category:Diseases]]
[[Category:Diseases]]
[[Category:Recently Added Pages]]
[[Category:Kidney]]
__TOC__
__TOC__
== Contributors ==
== Contributors ==
Daynna Wolff PhD FACMG
Han, Peng Cheng, MD
<br>
Daynna Wolff, PhD FACMG
<br>
Yajuan Liu, PhD
Yajuan Liu, PhD
<br>
Rajyasree Emmadi, MD
Rajyasree Emmadi, MD
<br>
Banumathy Gowrishankar, PhD
Banumathy Gowrishankar, PhD
<br>
Jane Houldsworth, PhD
Jane Houldsworth, PhD
== Tumor Type ==
== Cancer Category/Type ==
Kidney tumor<ref name=diaz></ref>
== Tumor Classification ==
== Cancer Sub-Classification/Subtype ==
Renal Oncocytoma
Renal Oncocytoma
== Description ==
== Description/Description of Disease ==
Renal oncocytoma (RO) is a benign but relatively rare renal epithelial tumor. Renal oncocytoma is postulated to originate from intercalated cells of collecting ducts, sharing the common origin with chromophobe renal cell carcinoma, a malignant form of kidney cancer Oncocytomas are the most frequent renal tumors in patients with Birt-Hogg-Dube syndrome (BHD). BHD is caused by mutations in the folliculin gene (FLCN). The etiology of sporadic RO is not known.
Oncocytoma is a benign renal epithelial
Oncocytoma is a benign renal epithelial
neoplasm and account for 5%
neoplasm and accounts for 5%
of the tumors derived from tubular epithelium (Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors.
of the tumors derived from tubular epithelium. <ref name=diaz>Diaz JI, Mora LB, Hakam A. The Mainz Classification of Renal Cell Tumors. Cancer Control. 1999 Nov;6(6):571-579.</ref><ref name=durinck>Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S. Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet. 2015 Jan;47(1):13-21.</ref><ref name=joshi>Joshi S, Tolkunov D, Aviv H, Hakimi AA, Yao M, Hsieh JJ, Ganesan S, Chan CS, White E. The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. Cell Rep. 2015 Dec 1;13(9):1895-908.</ref>
Cancer Control. 1999 Nov;6(6):571-579)
== Synonyms/Terminology ==
==Epidemiology/Prevalence ==
Renal oncocytomas comprise approximately 3-7% of renal epithelial neoplasms and have a slight higher prevalence in male (male: female ratio= 2~3:1)
== Clinical Features ==
Most cases are incidental findings with imaging without presenting symptoms, and treated with partial nephrectomy. Most oncocytoma behave in a benign fashion with no recurrence, metastasis or mortality.
==Sites of Involvement ==
Renal cortex or cortico-medullary junction
== Morphologic Features ==
Renal oncocytomas are solitary, well-circumscribed tumors with generally mahogany brown or dark red cut surface and frequently a central scar. Necrosis and hemorrhage are uncommon. Histologically, the overall architecture is nests, tubulocystic, solid, or trabecular patterns within myxomatous or hyalinized stroma. The cytologic features include homogenous, round and centrally located nuclei with diffuse eosinophilic cytoplasm that consists of multiple mitochondria, as revealed by electronic microscopy.
== IHC Markers ==
== Immunophenotype ==
Positive: [[CD10]], [[E-cadherin]], [[EMA]], [[PAX2]], [[PAX8]], [[CD117]], [[AMACR]].
Positive (universal): [[CD10]], [[E-cadherin]], [[EMA]], [[PAX2]], [[PAX8]], [[AMACR]].
Positive (subset): [CD117].
== Genomic Gain/Loss/LOH ==
Negative (universal): [[vimentin]], [[CD10]], [[RCC]], [[CK7]].
Negative (subset): [[CK7]],[[AMACR]].
== Genomic Gain/Loss/LOH<ref name=hagenkord>Hagenkord JM, Parwani AV, Lyons-Weiler MA, Alvarez K, Amato R, Gatalica Z, Gonzalez-Berjon JM, Peterson L, Dhir R, Monzon FA. Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors.</ref> ==
|1 || Loss || Chr1
|1 || Loss || Chr1
|-
|-
|2 || Loss || Chr14
|14 || Loss || Chr14
|-
|-
|3 || Loss || Chr21
|21 || Loss || Chr21
|-
|-
|4 || Loss || ChrX
|X || Loss || ChrX
|-
|-
|5 || Loss || ChrY (male)
|Y || Loss || ChrY (male)
|}
|}
== Rearrangements ==
== Rearrangements ==
CCND1 (11q13.3)
[[CCND1]] (11q13.3)<ref name=joshi></ref>
== Mutations (SNV/INDEL) ==
== Mutations (SNV/INDEL) ==
=== From Cosmic Mutated in >20% ===
=== From Cosmic Mutated in >20%<ref name=cosmic>COSMIC (http://cancer.sanger.ac.uk/cosmic)</ref> ===
=== Mutated in 10-20% ===
=== Mutated in 10-20% ===
=== Mutated in 5-10% ===
=== Mutated in 5-10% ===
== Main Pathways Involved ==
== Main Pathways Involved ==
Mitochrondrial electron transport chain, autophagy and golgi trafficking.
Mitochrondrial electron transport chain, autophagy and golgi trafficking.<ref name=joshi></ref>
== Diagnosis ==
== Diagnosis ==
Diploid with CCND1 rearrangement (Type I); Loss of 1, 14, 21, X or Y (Type II)
Diploid with CCND1 rearrangement (Type I); Loss of 1, 14, 21, X or Y (Type II)<ref name=joshi></ref>
== Prognosis ==
== Prognosis ==
Type II is more aggressive and may progress to malignant eosinophillic chrRCC.
Type II is more aggressive and may progress to malignant eosinophillic chrRCC.<ref name=diaz></ref><ref name=joshi></ref>
== Therapeutics ==
== Familial Forms ==
Birt-Hogg-Dube syndrome (BHD): FLCN (17p11.2)
== Links ==
== Links ==
==References==
==References==